| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/28/2009 | US20090136446 Induction of regulatory t cell-resistant helper cd4+ t cells |
| 05/28/2009 | US20090136427 LIGHT Inhibitors For Asthma, Lung and Airway Inflammation, Respiratory, Interstitial, Pulmonary and Fibrotic Disease Treatment |
| 05/28/2009 | US20090136420 Neoplasm-specific polypeptides and their uses |
| 05/28/2009 | CA2706514A1 Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same |
| 05/28/2009 | CA2706404A1 Preparation for body surface application and preparation for body suface application-holding sheet |
| 05/28/2009 | CA2706304A1 Modulation of the immune response |
| 05/28/2009 | CA2706204A1 Method for producing multiple modifications in the chromosome of gram-negative bacteria and salmonella strains which are deficient in c-di-gmp synthesis obtained by said method |
| 05/28/2009 | CA2706201A1 Peptides with capacity to bind to scurfin and applications |
| 05/28/2009 | CA2705588A1 System for delivery into a xcr1 positive cell and uses thereof |
| 05/28/2009 | CA2705544A1 Bioactive copepod-compositions, processes for the production thereof, and use thereof to prevent or treat hosts infested by phylogenetically similar ectoparasites |
| 05/27/2009 | EP2062972A1 Novel vaccine for dog |
| 05/27/2009 | EP2062919A2 Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors |
| 05/27/2009 | EP2062918A2 Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors |
| 05/27/2009 | EP2062917A2 Antibodies to erythropoietin receptor and uses thereof |
| 05/27/2009 | EP2062916A2 Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor |
| 05/27/2009 | EP2062915A2 Immunoglobulin fractions |
| 05/27/2009 | EP2062597A1 Preventive or remedy for er-negative and her2-negative breast cancer and method of screening the same |
| 05/27/2009 | EP2062596A1 Anti-tumor agent |
| 05/27/2009 | EP2062595A1 Inhibition of inflammation using alpha 7 receptor-binding cholinergic agonists |
| 05/27/2009 | EP2062594A1 Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same |
| 05/27/2009 | EP2062592A1 System for delivery into a XCR1 positive cell and uses thereof |
| 05/27/2009 | EP2062590A1 Peptide derived from Hepatitis C virus |
| 05/27/2009 | EP2062246A2 Chimeric virus vaccines |
| 05/27/2009 | EP2062023A2 Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus |
| 05/27/2009 | EP2061907A2 Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181 |
| 05/27/2009 | EP2061888A2 Hcv fusion polypeptides |
| 05/27/2009 | EP2061814A2 Antibodies and immunoconjugates and uses therefor |
| 05/27/2009 | EP2061812A1 Method for producing antibodies |
| 05/27/2009 | EP2061811A2 Variable region sequences of il-31 monoclonal antibodies and methods of use |
| 05/27/2009 | EP2061805A1 Recombinant hcv e2 glycoprotein |
| 05/27/2009 | EP2061804A2 Pax2 and pax8 as targets for immunologic and molecular tumour treatment strategies |
| 05/27/2009 | EP2061800A2 Compositions comprising hmw-maa and fragments thereof, and methods of use thereof |
| 05/27/2009 | EP2061511A2 Smallpox monoclonal antibody |
| 05/27/2009 | EP2061510A1 Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions |
| 05/27/2009 | EP2061509A2 Polymer-surfactant nanoparticles for sustained release of compounds |
| 05/27/2009 | EP2061508A2 Alphavirus replicon particles matched to protein antigens as immunological adjuvants |
| 05/27/2009 | EP2061507A2 Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of hiv-1 |
| 05/27/2009 | EP2061506A2 Vaccine composition and immunization method |
| 05/27/2009 | EP2061505A2 Composition for eliciting a specific ctl response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells |
| 05/27/2009 | EP2061503A2 Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| 05/27/2009 | EP2061502A2 Carbohydrate-based vaccines for hlv |
| 05/27/2009 | EP2061499A2 Novel nematode protein and its use in producing anthelminthic agents and vaccines |
| 05/27/2009 | EP2061490A1 Modulators of candida hyphal morphogenesis and uses thereof |
| 05/27/2009 | EP2061464A2 Combination therapy for tumoral disease treatment |
| 05/27/2009 | EP1753454B1 Vaccine for periodontal disease |
| 05/27/2009 | EP1651666B1 Alphavirus-based cytomegalovirus vaccines |
| 05/27/2009 | EP1567189B1 Malaria vaccine |
| 05/27/2009 | EP1548032B1 Kdr peptides and vaccines comprising the same |
| 05/27/2009 | EP1337554B1 Novel compounds |
| 05/27/2009 | EP1200476B1 Antitumor antibodies, proteins, and uses thereof |
| 05/27/2009 | EP1156826B1 Product and method for treatment of conditions associated with receptor-desensitization |
| 05/27/2009 | EP1037651B1 Small peptides and methods for treatment of asthma and inflammation |
| 05/27/2009 | EP1003850B1 Inhibitors of dna immunostimulatory sequence activity |
| 05/27/2009 | EP0959899B1 LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T CELL ACTIVATION AND PROLIFERATION |
| 05/27/2009 | EP0939796B1 Uses of oncofetal antigen specific cd4, cd8 cytotoxic and suppressor t cells and interleukin-10 |
| 05/27/2009 | EP0871487B1 Dendritic cell stimulatory factor |
| 05/27/2009 | CN101443361A Antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK |
| 05/27/2009 | CN101443360A Binding member for GM-CSF receptor |
| 05/27/2009 | CN101443043A Antibody compositions and methods |
| 05/27/2009 | CN101443042A Use of IL-1 antibodies for treating ophthalmic disorders |
| 05/27/2009 | CN101443041A Method and means for treating inflammatory bowel disease |
| 05/27/2009 | CN101443040A Methods of treating lupus using CD4 antibodies |
| 05/27/2009 | CN101443039A Compositions and methods for immunisation using CD1D ligands |
| 05/27/2009 | CN101443038A Nicotine-carrier vaccine formulation |
| 05/27/2009 | CN101443037A Pharmaceutical compositions containing protein NMA0939 |
| 05/27/2009 | CN101443036A Reagents and methods for cancer treatment and prevention |
| 05/27/2009 | CN101443035A Vaccine for treatment or prophylaxis therapy of myasthenia gravis |
| 05/27/2009 | CN101443034A Allergic inhibitor composition and kit and use method thereof |
| 05/27/2009 | CN101440359A Avian influenza viral vaccine and preparation thereof |
| 05/27/2009 | CN101440130A Variable regions of heavy chain and light chain of antihuman IL-13R alpha 2 monoclonal antibody |
| 05/27/2009 | CN100491531C Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of non-essential gene |
| 05/27/2009 | CN100491530C Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences |
| 05/27/2009 | CN100491403C Modified saccharides having improved stability in water |
| 05/27/2009 | CN100491398C Method of manufacturing human antibody possessing bioreceptor synergist, antagonist and/or inverse synergist |
| 05/27/2009 | CN100490896C Chewing tablet for discharging lead, and preparation method |
| 05/27/2009 | CN100490895C CD40-binding APC-activating molecules |
| 05/27/2009 | CN100490894C Immunotherapic agent which is used for the combined treatment of tuberculosis together with other pharmaceuticals |
| 05/26/2009 | US7538258 Transgenic nonhuman animal having germ or somatic cell containing nucleic acid encoding human amyloid precursor protein including nucleotides encoding codon 670 and 671; diagnosing and/or predicting predisposition; drug screening |
| 05/26/2009 | US7538208 Expression vector comprising nucleotide sequences coding portion of ADP-ribosylating toxin for use treatment and prevention of gramnegative bacterial infection |
| 05/26/2009 | US7538207 Polyepitope carrier protein |
| 05/26/2009 | US7538206 Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses |
| 05/26/2009 | US7538201 Viral particle comprising nucleotide sequences coding gB gene of infectious laryngotracheitis virus for use in generation of vaccine to prevent respiratory system disorders |
| 05/26/2009 | US7538196 Immunoglobulin comprising epitopes for tumor-associated cell-surface antigen and CD-28 for use in diagnosis, prevention and treatment of cell proliferative disorders |
| 05/26/2009 | US7538195 Antibodies that bind to human insulin-like growth factor-I receptor; particularly, antibodies that inhibit the cellular functions of the IGF-I receptor; cancer treatment |
| 05/26/2009 | US7538183 HPV vaccine comprising peptides from host cell proteins |
| 05/26/2009 | US7538182 conjugated by bridging molecules to proteins or polypeptides, reporter groups or cytotoxic agents; cancer |
| 05/26/2009 | US7538097 Inhibition of antigen presentation with poorly catabolized polymers |
| 05/26/2009 | US7538086 Nucleotide sequences coding polypeptide for use in the treatment, diagnosis and prevention of cell proliferative disorders |
| 05/26/2009 | US7538083 Compositions and methods for the potentiation of immune responses against target antigens |
| 05/26/2009 | US7537931 a cancer which expresses epidermal growth factor receptor; blocking ligand activation of a receptor; binding of monoclonal antibody 2C4 to ErbB2; chemotherapeutic agents are 5-fluorouracil leucovorin, levamisole |
| 05/26/2009 | US7537908 Using concentration of high mobility group 1 (HMG1) protein as evaluative tool in detection of infection and acute respiratory distress syndrome; treating obesity with high mobility group antagonist |
| 05/26/2009 | US7537887 Relates to regulation of activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity; methods of screening for agonists or antagonists of NET in order to identify new pro- or anti-angiogenic compounds |
| 05/26/2009 | US7537772 Chlamydia protein, gene sequence and the uses thereof |
| 05/26/2009 | US7537771 Produces an immune response which is protective against Bacillus anthracis |
| 05/26/2009 | US7537770 Attenuation of cytomegalovirus virulence |
| 05/26/2009 | US7537769 Webbed immunogens comprising recombinant human immunodeficiency virus (HIV) envelope glycoproteins and the M9 scorpion toxin |
| 05/26/2009 | US7537768 Influenza virus vaccine composition and methods of use |
| 05/26/2009 | US7537767 Melan-A- carrier conjugates |
| 05/26/2009 | US7537766 two 2-aminoethyl phosphate PEA units simultaneously attached to the HepII residue of the inner core; 3-(2-pyridyldithio)-propionyl hydrazide linker molecule; serogroups A, B, C, Y, W135 |
| 05/26/2009 | US7537765 Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein |